@article{de_paiva_what_2020,
	title = {What is holding back the development of antiviral metallodrugs? {A} literature overview and implications for {SARS}-{CoV}-2 therapeutics and future viral outbreaks},
	volume = {49},
	issn = {1477-9226, 1477-9234},
	shorttitle = {What is holding back the development of antiviral metallodrugs?},
	url = {https://xlink.rsc.org/?DOI=D0DT02478C},
	doi = {10.1039/D0DT02478C},
	abstract = {Despite a significative classical literature, metallodrugs have struggled to reach clinical practice. In light of the COVID-19 outbreak, this review aims at further encouraging and promoting the development of metallodrugs as viable antiviral agents.
          , 
            In light of the Covid-19 outbreak, this review brings together historical and current literature efforts towards the development of antiviral metallodrugs. Classical compounds such as CTC-96 and auranofin are discussed in depth, as pillars for future metallodrug development. From the recent literature, both cell-based results and biophysical assays against potential viral biomolecule targets are summarized here. The comprehension of the biomolecular targets and their interactions with coordination compounds are emphasized as fundamental strategies that will foment further development of metal-based antivirals. We also discuss other possible and unexplored methods for unveiling metallodrug interactions with biomolecules related to viral replication and highlight the specific challenges involved in the development of antiviral metallodrugs.},
	language = {en},
	number = {45},
	urldate = {2024-10-24},
	journal = {Dalton Transactions},
	author = {De Paiva, Raphael E. F. and Marçal Neto, Antônio and Santos, Igor A. and Jardim, Ana C. G. and Corbi, Pedro P. and Bergamini, Fernando R. G.},
	year = {2020},
	pages = {16004--16033},
}

{"_id":"EgB8ooeGTw2oxmAf7","bibbaseid":"depaiva-maralneto-santos-jardim-corbi-bergamini-whatisholdingbackthedevelopmentofantiviralmetallodrugsaliteratureoverviewandimplicationsforsarscov2therapeuticsandfutureviraloutbreaks-2020","authorIDs":["m3HgPrLB3PrXd3Nad"],"author_short":["De Paiva, R. E. F.","Marçal Neto, A.","Santos, I. A.","Jardim, A. C. G.","Corbi, P. P.","Bergamini, F. R. G."],"bibdata":{"bibtype":"article","type":"article","title":"What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks","volume":"49","issn":"1477-9226, 1477-9234","shorttitle":"What is holding back the development of antiviral metallodrugs?","url":"https://xlink.rsc.org/?DOI=D0DT02478C","doi":"10.1039/D0DT02478C","abstract":"Despite a significative classical literature, metallodrugs have struggled to reach clinical practice. In light of the COVID-19 outbreak, this review aims at further encouraging and promoting the development of metallodrugs as viable antiviral agents. , In light of the Covid-19 outbreak, this review brings together historical and current literature efforts towards the development of antiviral metallodrugs. Classical compounds such as CTC-96 and auranofin are discussed in depth, as pillars for future metallodrug development. From the recent literature, both cell-based results and biophysical assays against potential viral biomolecule targets are summarized here. The comprehension of the biomolecular targets and their interactions with coordination compounds are emphasized as fundamental strategies that will foment further development of metal-based antivirals. We also discuss other possible and unexplored methods for unveiling metallodrug interactions with biomolecules related to viral replication and highlight the specific challenges involved in the development of antiviral metallodrugs.","language":"en","number":"45","urldate":"2024-10-24","journal":"Dalton Transactions","author":[{"propositions":[],"lastnames":["De","Paiva"],"firstnames":["Raphael","E.","F."],"suffixes":[]},{"propositions":[],"lastnames":["Marçal","Neto"],"firstnames":["Antônio"],"suffixes":[]},{"propositions":[],"lastnames":["Santos"],"firstnames":["Igor","A."],"suffixes":[]},{"propositions":[],"lastnames":["Jardim"],"firstnames":["Ana","C.","G."],"suffixes":[]},{"propositions":[],"lastnames":["Corbi"],"firstnames":["Pedro","P."],"suffixes":[]},{"propositions":[],"lastnames":["Bergamini"],"firstnames":["Fernando","R.","G."],"suffixes":[]}],"year":"2020","pages":"16004–16033","bibtex":"@article{de_paiva_what_2020,\n\ttitle = {What is holding back the development of antiviral metallodrugs? {A} literature overview and implications for {SARS}-{CoV}-2 therapeutics and future viral outbreaks},\n\tvolume = {49},\n\tissn = {1477-9226, 1477-9234},\n\tshorttitle = {What is holding back the development of antiviral metallodrugs?},\n\turl = {https://xlink.rsc.org/?DOI=D0DT02478C},\n\tdoi = {10.1039/D0DT02478C},\n\tabstract = {Despite a significative classical literature, metallodrugs have struggled to reach clinical practice. In light of the COVID-19 outbreak, this review aims at further encouraging and promoting the development of metallodrugs as viable antiviral agents.\n , \n In light of the Covid-19 outbreak, this review brings together historical and current literature efforts towards the development of antiviral metallodrugs. Classical compounds such as CTC-96 and auranofin are discussed in depth, as pillars for future metallodrug development. From the recent literature, both cell-based results and biophysical assays against potential viral biomolecule targets are summarized here. The comprehension of the biomolecular targets and their interactions with coordination compounds are emphasized as fundamental strategies that will foment further development of metal-based antivirals. We also discuss other possible and unexplored methods for unveiling metallodrug interactions with biomolecules related to viral replication and highlight the specific challenges involved in the development of antiviral metallodrugs.},\n\tlanguage = {en},\n\tnumber = {45},\n\turldate = {2024-10-24},\n\tjournal = {Dalton Transactions},\n\tauthor = {De Paiva, Raphael E. F. and Marçal Neto, Antônio and Santos, Igor A. and Jardim, Ana C. G. and Corbi, Pedro P. and Bergamini, Fernando R. G.},\n\tyear = {2020},\n\tpages = {16004--16033},\n}\n\n","author_short":["De Paiva, R. E. F.","Marçal Neto, A.","Santos, I. A.","Jardim, A. C. G.","Corbi, P. P.","Bergamini, F. R. G."],"key":"de_paiva_what_2020","id":"de_paiva_what_2020","bibbaseid":"depaiva-maralneto-santos-jardim-corbi-bergamini-whatisholdingbackthedevelopmentofantiviralmetallodrugsaliteratureoverviewandimplicationsforsarscov2therapeuticsandfutureviraloutbreaks-2020","role":"author","urls":{"Paper":"https://xlink.rsc.org/?DOI=D0DT02478C"},"metadata":{"authorlinks":{"bergamini, f":"https://bibbase.org/service/mendeley/6d4e9e22-09e3-3340-83ee-25b0de1090e1/group/edb17a89-a16c-3c5d-8f2a-ce318aa08fb4"}},"downloads":0},"bibtype":"article","creationDate":"2021-03-12T20:46:40.850Z","downloads":0,"keywords":[],"search_terms":["holding","back","development","antiviral","metallodrugs","literature","overview","implications","sars","cov","therapeutics","future","viral","outbreaks","de paiva","marçal neto","santos","jardim","corbi","bergamini"],"title":"What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks","year":2020,"biburl":"https://api.zotero.org/users/1360635/collections/D6QTG5L9/items?key=M1LYgnALYcuEPooCBFXCVgWF&format=bibtex&limit=100","dataSources":["qshhWLKQydZqDJekD","ya2CyA73rpZseyrZ8","2252seNhipfTmjEBQ","8JzyX5ddx5f6obrhn","o2mL7kG99iAQPpNRJ"]}